Development, impact and outcomes of the Hull Bacteraemia Service

QJM: An International Journal of Medicine

Volumn 101, Issue 11, 2008, Pages 889-898

  Lillie, P ^a   Moss, P ^a   Thaker, H ^a   Parsonage, M ^a   Adams, K ^a   Meigh, J ^b   Meigh, R ^b   Mawer, S ^b   Dibb, W ^b   Wilson, J ^b   Musaad, S ^b   O'brien, P ^c   Barlow, Gavin ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b Department of Medical Microbiology ^*  (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; FLUCLOXACILLIN; LINEZOLID; MACROLIDE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN;

ADULT; AGED; ARTICLE; BACTEREMIA; CENTRAL VENOUS CATHETERIZATION; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS;

EID: 54949094395     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn114     Document Type: Article

References (22)

1. Elhanan G, Raz R, Pitlik SD, Sharir R, Konisberger H, Samara Z, et al Bacteraemia in a community and a university hospital. J Antimicrob Chemother 1995; 36:681-95.
2. Lark RL, Saint S, Chenoweth C, Zemencuk JK, Lipsky BA, Plorde JJ. Four-year prospective evaluation of community acquired bacteraemia: epidemiology, microbiology, and patient outcome. Diagn Microbiol Infect Dis 2001; 41:15-22.
3. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteraemia. Diagn Micrbiol Infect Dis 2005; 52:113-22.
4. Pirson M, Dramaix M, Struelens M, Riley TV, Leclercq P. Costs associated with hospital-acquired bacteraemia in a Belgian hospital. J Hosp Infect 2005; 59:33-40.
5. Chu VH, Crosslin DR, Friedman JY, Read SD, Cabell CH, Griffiths RI. Staphylococccus aureus bacteraemia in patients with prosthetic devices: costs and outcomes. Am J Med 2005; 118:1416.
6. Kang CI, Kim SH, Kim HB, Park SW, Choe YS, Kim BK, et al. Pseudomonas aeruginosa bacteraemia: Risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-51.
7. Kuikka A, Sivonen A, Emelianova A, Valtonen VV. Prognostic factors associated with improved outcome of Escherichia coli bacteraemia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1997; 16:125-34.
8. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller M. Treatment and outcome of Staphylococcus aureus bacteraemia: A prospective study of 278 cases. Arch of Intern Med 2002; 162:25-32.
9. Weinstein MP, Towns ML, Quartey SM, Mirret S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteraemia and fungaemia in adults. Clin Infect Dis 1997; 24:584-602.
10. Johnson LB, Almoujahmed MO, Ilg K, Maolood L, Khatib R. Staphylococcus aureus bacteraemia: Compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35 782-9.
11. Fowler VG, Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, et al. Outcome of Staphylococcus aureus bacteraemia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27 478-86.
12. Kaech C, Elzi L, Sendi P, Frei R, Laifer G, Basseti S, et al. Course and outcome of Staphylococcus aureus bacteraemia: A retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Micro Infect 2006; 12:345-52.
13. Cunney RJ, McNamara EB, Alansari N, Loo B, Smyth EJ. The impact of blood culture reporting and clinical liaison on the empiric treatment of bacteraemia. J Clin Pathol 1997; 50:1010-2.
14. Wolf S, Leitritz L, Rupp C, Schlorndorff D, Bogner JR. Cost reduction after introduction of a multi-disciplinary infectious disease service at a German university hospital. Infection 2000; 28:379-83.
15. Nathwani D, Davey P, France AJ, Phillips G, Orange G, Parrat D. Impact of an infection consultation service for bacteraemia on clinical management and use of resources. QJM 1996; 89:789-97.
16. Bouza E, Sousa D, Munoz P, Rodriguez-Creixems M, Fron C, Lechuz JG. Bloodstream infections: A trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis 2004; 39:1161-9.
17. Berild D, Mohseni A, Diep LM, Jensenius M, Ringertz SH. Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs. J Antimicrob Chemother 2006; 57:326-30.
18. Minton J, Clayton J, Sandoe J, McGann H, Wilcox M. Improving early management of bloodstream infection: A quality improvement project. BMJ 2008; 336:440-3.
19. Madsen KM, Schønheyder HC, Kristensen B, Sørensen HT. Secular trends in incidence and mortality of bacteraemia in Danish county 1981-1994. APMIS 1999; 107:346-52.
20. Das I, O'Connell N, Lambert P. Epidemiology, clinical and laboratory characteristics of Staphylococcus aureus bacteraemia in a university hospital in UK. J Hosp Infect 2007; 65:117-23.
21. Wyllie D, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: Cohort study. BMJ 2006; 333:281-6.
22. Ziglam HM, Morales D, Webb K, Nathwani D. Knowledge about sepsis among training-grade doctors. J Antimicrob Chemother 2006; 57 963-5.